Tubulin alpha 1b (TUBA1B) is an important microtubule isoform that is involved in the formation of the cytoskeleton. The objective of our study was to explore the potential of TUBA1B in predicting the prognosis of HCC and patients’ response to immunotherapy. Raw data was extracted from TCGA and GEO databases, and then HCCDB, TIMER, HPA, and GEPIA websites, as well as R software, were used to perform bioinformatics analysis to investigate the potential of TUBA1B as a prognostic and immunotherapeutic marker for hepatocellular carcinoma (HCC). We found that both TUBA1B mRNA and protein were highly expressed in HCC. TUBA1B was proved to be an independent prognostic predictor of HCC. Additionally, TUBA1B expression was associated with the infiltration of several immune cells in HCC. Moreover, TUBA1B was coexpressed with immune-related genes and immune checkpoints. Patients expressing high TUBA1B responded better to immune checkpoint inhibitor (ICI) therapy. GO and KEGG analyses revealed that TUBA1B may be involved in the processes of cell cycle, spliceosome, and DNA replication. In conclusion, TUBA1B is expected to be a prognostic and immunotherapeutic marker for HCC.
Malignant tumors are always a critical threat to human health, with complex pathogenesis, numerous causative factors, and poor prognosis. The features of cancers, such as gene mutations, epigenetic alterations, and the activation and inhibition of signaling pathways in the organism, play important roles in tumorigenesis and prognosis. MicroRNA (miRNA) enables the control of various molecular mechanisms and plays a variety of roles in human cancers, such as radiation sensitivity and tumor immunity, through the regulation of target genes. MiR-149-5p participates in the process and is closely related to lipogenesis, the migration of vascular endothelial cells, and the expression of stem-cell-related proteins. In recent years, its role in cancer has dramatically increased. In this review, we summarize the regular physiological roles of miRNAs, specifically miR-149-5p, in the organism and discuss the tumor-suppressive or oncogenic roles of miR-149-5p in different human cancers with respect to signaling pathways involved in regulation. Possible clinical applications of miR-149-5p in future targeted therapies and prognosis improvement in oncology are suggested.
Hepatocellular carcinoma (HCC) is one of the most common cancers and the fourth leading cause of death in men. YEATS domain containing 2 (YEATS2) gene encodes a scaffolding subunit of the ATAC complex. We found that YEATS2 was upregulated in HCC tissues and was associated with a poor prognosis. However, the role of YEATS2 in HCC remains unclear. The purpose of this study was to investigate the effect of YEATS2 on the progression of HCC and to elucidate its related mechanisms. We found that overexpression of YEATS2 promoted tumor cell proliferation, migration, and invasion through the PI3K/AKT signaling pathway and regulation of extracellular matrix. These findings help to understand the role of YEATS2 in HCC, and YEATS2 may become a new target for HCC therapy.
27 December 2025 in International Immunopharmacology
Hepatocellular carcinoma (HCC) is a highly aggressive liver malignancy with poor prognosis and limited therapeutic options. Methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2), a mitochondrial enzyme involved in one‑carbon metabolism, is frequently upregulated in cancers; however, its role and regulatory mechanisms in HCC remain poorly defined. In this study, we show that MTHFD2 is significantly overexpressed in HCC and correlated with increased tumor cell proliferation and poor prognosis. MTHFD2 knockdown significantly impaired HCC cell proliferation, invasion, and metastasis, while enhancing CD8+ T cell-mediated cytotoxic responses. Mechanistically, UBE2C facilitated PTEN ubiquitination and subsequent degradation, leading to activation of the PI3K/AKT/mTOR signaling cascade and upregulation of MTHFD2 transcription mediated by transcription factor ATF4. MTHFD2 maintained redox homeostasis and upregulated PD-L1 expression, thereby driving tumor development. Inhibition of the UBE2C-MTHFD2 axis suppressed HCC development in vivo models. Furthermore, expression levels of UBE2C and MTHFD2 are positively correlated and independently associated with poor prognosis in HCC patients. Collectively, these findings establish UBE2C as a key upstream regulator of MTHFD2 and highlight MTHFD2 as a promising therapeutic target for HCC.
23 June 2023 in Clinical and Translational Oncology